Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies.
According to a release, the study will take place in up to 15 centers in the United States for patients with a variety of orphan-designated relapse or refractory hematologic cancers. Read the full story here.
Hear from former winners of the #Wisconsin Governor's Business Plan Contest at our #Innovation Network Luncheon on 5/9 the @uwm's Innovation Accelerator in Wauwatosa!
Learn more and register: https://loom.ly/npKwq2Y #startup
Check out the latest #tech- and #entrepreneurial-related news, events and #jobopportunities in our newsletter! https://loom.ly/xG_9cJ0
.@gener8tor #Madison invests $600k in six startups. https://loom.ly/onW9GQQ #entrepreneur #startup
.@uwhealth: Clinical trial examines new way of eliminating kidney stones. https://loom.ly/kvnwoIU via @wisbusiness #clinicaltrials #clinicalresearch
Clinical trial examines new way of eliminating kidney stones. https://loom.ly/KWAtQT0 via @wisbusiness #clinicaltrials #clinialresearch
.@uwgb, @stnorbert #partnership lets #students study at both schools. via @wpr #education
UW-Green Bay, St. Norbert partnership lets students study at both schools
The University of Wisconsin-Green Bay and St. Norbert College are partnering to let students seamlessly study at both schools beginning this fall.
loom.ly
;
